NALP3 Activation Triggers Development of AMD
Principal Investigator
Bruce Ksander, PhD
Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, MA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$99,836
Active Dates
July 01, 2011 - June 30, 2013
Grant ID
M2011069
Goals
Age related Macular Degeneration (AMD) causes loss of vision and blindness in elderly patients when two types of cells are damaged (i) RPE (called retinal pigment epithelial cells), and (ii) photoreceptors. We discovered a gene (called NALP3) is expressed in retinal cells during the development of AMD. We predict this gene is important in triggering this disease via the activation of localized inflammation.
Summary
Retinal pigment epithelial (RPE) cells support the light‐detecting photoreceptor cells by recycling and removing waste products. If RPE cells are unhealthy, then this waste can build up and damage the retina. Inflammation is an important part of the AMD disease process, and RPE cells have their own special type of proteins—called the “inflammasome”—to monitor and determine if the RPE is working properly. In fact, if this RPE waste recycling and removal process isn’t functioning properly, the inflammasome sends out signals for the immune system to swoop in and kill the malfunctioning RPE cells. Dr. Ksander and collaborators have discovered a new risk gene—called NALP3— that is expressed in retinal cells and is suspected to be important in triggering AMD via the inflammasome. These researchers will determine whether this gene is involved in the death of RPE cells and, if so, whether it will be a new target for the treatment of AMD.
Grants
Related Grants
Macular Degeneration Research
Addressing the Link Between Impairment in Phagosome Degradation and AMD
Active Dates
July 01, 2021 - November 30, 2023
Principal Investigator
Antonio Escudero Paniagua, PhD
Addressing the Link Between Impairment in Phagosome Degradation and AMD
Active Dates
July 01, 2021 - November 30, 2023
Principal Investigator
Antonio Escudero Paniagua, PhD
Macular Degeneration Research
Novel Antibody-Based Agonist for Neovascular AMD
Active Dates
July 01, 2021 - June 30, 2023
Principal Investigator
Rony Chidiac, PhD
Novel Antibody-Based Agonist for Neovascular AMD
Active Dates
July 01, 2021 - June 30, 2023
Principal Investigator
Rony Chidiac, PhD
Macular Degeneration Research
A New Animal Model of Severe Age-Related Macular Degeneration
Active Dates
July 01, 2021 - June 30, 2024
Principal Investigator
Brittany Carr, PhD
A New Animal Model of Severe Age-Related Macular Degeneration
Active Dates
July 01, 2021 - June 30, 2024
Principal Investigator
Brittany Carr, PhD